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The role of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection is
poorly understood and was assessed by evaluating responses at different stages of infection. Undi-
luted sera from long-term nonprogressors (LTNP) had broad neutralizing antibodies against heterol-
ogous primary isolates and were more likely to neutralize the contemporaneous autologous isolate
than were sera from short-term nonprogressors and progressors. In primary infection, envelope-
specific IgG was detected before the initial decline in plasma viremia, but neutralizing antibodies
developed more slowly. Here, neutralizing antibodies against strains SF-2 and MN were sometimes
the first to be detected, but titers were low for at least 17 weeks from onset of symptoms. Neutralizing
antibodies against the early autologous isolate were detected for 4 patients by 5–40 weeks but were
undetectable in 2 additional patients for 27–45 weeks. The results indicate that neutralizing antibody
responses are slow to develop during primary infection and are uniquely broad in LTNP.
Infection with human immunodeficiency virus type 1 (HIV- Although most infected persons progress to AIDS within a
1) is accompanied by cellular and humoral immune responses median time of 10 years from initial seroconversion, 5%–
of various magnitudes and specificities that are thought to 10% tolerate infection without immune suppression or other
down-regulate plasma viremia during primary infection [1, 2] clinical manifestations for longer periods of time [13–15]. This
and to establish a period of clinical latency that follows [3]. latter group of infected persons is referred to as long-term
Despite the benefit provided by these responses early in infec- nonprogressors (LTNP). LTNP generally have low virus loads
tion, nearly all HIV-1–infected persons progress to AIDS. Spe- in their plasma, peripheral blood mononuclear cells (PBMC),
cific responses that are at least partially beneficial during the and lymph nodes and mount robust cellular and humoral im-
course of infection are poorly understood. Detection of HIV- mune responses [16–21]. Some cases of long-term nonprogres-
1–specific cytotoxic T lymphocytes (CTL) correlates well with sion are associated with infection by attenuated virus [22] or
the initial down-regulation of plasma viremia during primary with a heterozygous defect in the CCR5 co-receptor [23]. Many
infection [4–7] and could be a dominant antiviral immune other LTNP are thought to benefit from the overall quality of
response. Another correlate during primary infection is the their immune responses.
production of HIV-1–specific IgM [8] and possibly IgG [2, Previous studies showed that neutralizing antibody responses
9], but it is not clear whether these early antibodies are effective in LTNP are greater in magnitude and breadth than they are
against the virus. For example, neutralizing antibody responses in other HIV-1–infected persons. For example, the average
against the early autologous virus have been shown to be de- titer of neutralizing antibodies against HIV-1IIIB and HIV-1MN
layed relative to when plasma viremia is first down-regulated was significantly higher in sera from LTNP than from persons
[5–7, 10]. Similar delays in neutralizing antibody production who had been infected for 7 years and had no signs of
have been reported for simian immunodeficiency virus (SIV) immune suppression [17]. In addition, we [17] and others [18]
infection in macaques [11, 12]. This slow development of neu- determined that sera from LTNP neutralize heterologous pri-
tralizing antibodies during primary infection might be one of mary isolates more effectively than do sera from progressors.
the reasons the virus is able to establish persistent infection. Importantly, it was not clear from these studies whether the
greater capacity of sera from LTNP to neutralize primary iso-
lates was merely a reflection of diminished response in immu-
Received 10 December 1996; revised 28 April 1997.
nologically suppressed persons.Informed consent, as approved by local institutional review boards and
biosafety committees, was obtained from all patients and controls. The study The present study aimed to determine whether the broad
followed human experimentation guidelines of the US Department of Health neutralizing antibody responses seen in LTNP are unique com-
and Human Services.
pared with responses in other HIV-1–infected persons, includ-Financial support: NIH (AI-45218, AI-28662).
Reprints or correspondence: Dr. David C. Montefiori, Dept. of Surgery, Box ing short-term nonprogressors (STNP) who had been infected
2926, Duke University Medical Center, Durham, NC 27710. for 2–7 years. We took advantage of the fact that virus neutral-
The Journal of Infectious Diseases 1997;176:924–32 ization was more readily detected with undiluted serum sam-
q 1997 by The University of Chicago. All rights reserved.
0022–1899/97/7604–0011$02.00 ples. By use of this approach, neutralizing antibodies in sera
/ 9d35$$oc12 07-30-97 20:43:39 jinfa UC: J Infect
925JID 1997;176 (October) Neutralizing Antibodies in HIV Infection
Table 1. Characteristics of primary isolates from HIV-1–infectedfrom LTNP, progressors, recent seroconverters, and STNP
subjects.were evaluated with autologous and heterologous primary iso-
lates. We also determined whether low-level neutralizing anti-
p24 TCID50/ng
bodies might be present during primary infection that had pre- Group, isolate Phenotype TCID50 (ng/mL)* of p24
viously gone undetected. Sequential serum samples obtained
Progressorsduring and immediately following primary infection were as-
P59423 NSI 5.6 1 104 35.0 1600sessed for neutralizing antibodies against the early autologous
W25798 NSI 1.7 1 104 21.0 809virus and T cell line–adapted (TCLA) variants of HIV-1, in-
W79290 NSI 7.5 1 103 31.4 239
cluding IIIB, MN, and SF-2. V89872 SI 1.3 1 105 29.8 4362
V67970 SI 9.4 1 105 32.9 28,571
W179273 SI 3.3 1 105 12.0 27,500
STNPMethods
P46471 NSI 9.4 1 105 61.0 15,410
T00953 NSI 1.3 1 105 57.9 2245Study participants. HIV-1–infected LTNP and progressors
V91008 NSI 1.6 1 106 109.0 14,679were described previously [16, 17]. LTNP had well-documented
W97464 NSI 9.4 1 105 39.6 23,738
infection for ⁄10 years, were asymptomatic, and had 600 CD4
LTNP
T lymphocytes/mm3 in their peripheral blood; these levels were 18 NSI 1.9 1 105 53.5 3551
stable over time. With the exception of 1 LTNP (no. 17), no 22 NSI 1.9 1 105 600.0 317
LTNP received antiretroviral therapy. All progressors had signs 24 NSI 1.3 1 105 67.7 1920
of immunosuppression as evidenced by low CD4 T lymphocyte Primary infection
15 NSI 4.7 1 106 124.8 37,660counts (range, 10–371/mm3). A group of STNP, defined as having
23 NSI 1.9 1 105 44.8 4241documented infection for 2–7 years but remaining healthy, with
27 NSI 2.8 1 105 25.3 11,067600 CD4 T lymphocytes/mm3, were recruited from the Durham,
30 NSI 2.1 1 106 60.0 35,000North Carolina, area. Information about antiretroviral therapy for
45 NSI 3.8 1 104 4.7 8085progressors and STNP was unavailable.
46 NSI 2.1 1 106 41.0 51,220
Six persons with primary HIV-1 infection were referred for
study by their private physicians. Each of them had developed NOTE. STNP, short-term nonprogressors; LTNP, long-term nonpro-
transient mild clinical symptoms, which brought them to the atten- gressors; SI, syncytium-inducing; NSI, non–syncytium-inducing.
* Concentration of p24 at time of harvest from initial cocultivation.tion of their physicians. Four of them began antiretroviral therapy
within a few days of entry into study. Exceptions were patient 45,
who received no antiretroviral therapy during the course of study,
and patient 46, who began antiretroviral therapy 25 weeks from of cells (5 1 104/well). Cultures were then incubated for the mini-
mum length of time that allowed for extensive syncytium forma-the onset of symptoms. Healthy, HIV-1–negative persons were
recruited from local research laboratories. tion to occur, as observed microscopically (3–4 days). Cell viabil-
ity was quantified by neutral red staining as described [25].Primary isolates. Viruses were isolated by coculture of PBMC
from infected persons with phytohemagglutinin-stimulated PBMC Percentage of protection was calculated by the difference in ab-
sorbance at 540 nm between test wells (cells, serum sample, and(PHA-PBMC) from healthy, noninfected persons in the presence
of interleukin-2 (IL-2) as described [17]. Primary isolates from virus) and virus control wells (cells and virus) divided by the
difference in absorbance between cell control wells (cells only)acute seroconverters were obtained at the time of their first serum
collection. Virus stocks were made cell-free by low-speed centrifu- and virus control wells. Neutralization titers were defined as the
reciprocal of the serum dilution required to protect at least 50%gation and passage through 0.5-mm cellulose acetate filters before
being stored in aliquots at 0707C. Some stocks were later ex- of cells from virus-induced killing. Assays were standardized by
including positive and negative control sera that had been assayedpanded a single time in PHA-PBMC. TCID50 was determined by
the method of Reed and Muench [24] after 14 days of incubation multiple times and for which the average titer was well-character-
ized. Virus stocks for these assays were produced in H9 cells.with PHA-PBMC. Viral antigen concentration was measured by
p24 immunoassay (DuPont, Wilmington, DE). Syncytium-induc- Antibody-mediated neutralization of primary isolates was mea-
sured in PHA-PBMC as described [17] by use of a p24 immunoas-ing (SI) and non-SI (NSI) phenotypes were determined in MT-2
cells and PHA-PBMC as described [17]. The TCID50 , p24 concen- say to quantify virus production. For assays with undiluted serum,
20 mL of cell-free virus was incubated with 80 mL of serum fortration, and phenotype of each virus stock are given in table 1.
Additional information on isolates obtained from LTNP and prog- 1 h at 377C, and 25 mL of this mixture was added to triplicate
wells containing PHA-PBMC (4 1 105 cells in 175 mL added perressors has been published [17]. Primary isolates were used as
either first- or second-passage stocks produced in PHA-PBMC. well). For measurement of titer, 50 mL of virus was incubated in
triplicate as above with an equal volume of serum samples thatSerologic assays. Neutralizing antibodies against TCLA
strains of HIV-1 were measured in MT-2 cells (strains IIIB and were undiluted and diluted 1:2, 1:4, 1:16, and 1:32 (dilutions were
made in IL-2 growth medium). Next, 25 mL was transfered toMN) or CEMx174 cells (strain SF-2) in 96-well plates by a reduc-
tion in virus-induced cell killing as described previously [25]. In corresponding wells of U-bottom plates containing PHA-PBMC.
Cells were incubated with the virus-serum mixtures for 3 h at 377Cbrief, cell-free virus (1000 TCID50) and serial dilutions of test sera
were incubated in triplicate at 377C for 30 min before the addition and then washed three times with 200 mL of growth medium to
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remove the virus inoculum and antibodies. Washed cells were Statistical analyses. The significance of the frequency by
which sera from paired groups of infected persons neutralizedsuspended in 250 mL of IL-2 growth medium and incubated in
96-well flat-bottom plates for the duration. Culture supernatants primary isolates in a panel of 6 isolates was evaluated by x2
analysis with 1 df. This analysis assumed that the ability of a(25 mL) were collected on a daily basis and mixed with 225 mL
of 0.5% Triton X-100 for the quantification of p24. This volume particular serum sample to neutralize one primary isolate does
not predict its ability to neutralize other primary isolates. Yates’swas replaced with 25 mL of fresh IL-2 growth medium at each
collection. correction factor was used to give a more conservative estimate
of P. Neutralization sensitivity of NSI and SI viruses was alsoViral p24 produced in the absence of test sera (virus control)
was determined for each daily sampling and was used to construct compared by x2 analysis, but here sera from all infected persons
were grouped as one. The small number of NSI and SI isolates (3a viral replication curve. Neutralization was measured at a time
when the concentration of p24 in virus control wells exceeded 5 each) did not permit a comparison of neutralization sensitivity
between sera from different subgroups of persons.ng/mL (limit of detection was 0.1 ng/mL) but had not reached
peak production (4–6 days). Serum samples were considered posi-
tive for primary isolate neutralization if they caused 80% reduc-
Resultstion in p24 relative to a negative control serum (D01). This cutoff
corresponds to a minimum 1 log reduction in infectious virus yield. Autologous and heterologous neutralizing antibody re-
Standard deviations for a given serum sample were divided by the sponses at different stages of HIV-1 infection. Serum samples
average p24 value of the virus control and then multiplied by 100
obtained at different stages of HIV-1 infection were assessed
for percentage. An equal volume of undiluted virus stock was used
for neutralization breadth with a panel of 6 primary isolates.for all assays. While the infectious dose contained within this
Sera from 6 recent seroconverters (sera obtained 13–53 weeksvolume was not the same for all isolates, each serum sample was
from onset of symptoms), 5 progressors, 6 STNP, 6 LTNP, andtested against an equal dose on a per-virus basis. Sera were heat-
5 healthy HIV-1–negative persons were used in this evaluationinactivated at 567C for 1 h before use.
Antibodies that bound to HIV-1 antigens were assessed by HIV- (table 2). Primary isolates were derived from the progressors
1IIIB Western immunoblot (Cambridge Biotech, Worcester, MA) listed in table 2. These same primary isolates and sera from
and by HIV-1MN gp160 ELISA. Baculovirus-derived HIV-1MN progressors and LTNP were used in a previous study in which
gp160 was obtained from Quality Biologicals (Gaithersburg, MD). the primary isolates were rarely neutralized by 1:16-diluted
ELISAs were done as described previously [26] with alkaline phos- serum samples [17]. Undiluted serum was used in the present
phatase–conjugated goat anti-human IgG (whole molecule; Sigma, study to improve the detection of neutralizing antibodies.
St. Louis) and p-nitrophenylphosphate disodium hexahydrate
No neutralization of primary isolates was detected with sera
(Sigma; catalog no. N-9389) used for detection and color develop-
from HIV-1–negative persons. In some cases, mild enhance-ment, respectively. Titers are reported as the reciprocal of the
ment of infection was observed with these sera, but the enhanc-highest serum dilution to produce an average absorbance reading
ing effect was never more than a doubling of p24 production,of at least twice that of a negative control serum (D01).
which would not be considered true enhancement [12, 17].Removal of IgG. IgG was removed from serum samples by
absorption with protein G–sepharose (GammaBind Plus Sepha- Neutralization of each virus was detected sporadically with
rose; Pharmacia, Piscataway, NJ). Protein G–sepharose was ob- serum samples from HIV-1–infected persons. Positive neutral-
tained by the supplier as a suspension in PBS containing thimerosal ization was detected most often with sera from LTNP. Of the
as a preservative. The resin was washed five times with PBS and LTNP sera evaluated, 20 (56%) of 36 virus-serum combina-
collected by low-speed centrifugation as premeasured aliquots after tions tested positive. Neutralization was detected less fre-
the last wash. Supernatants were removed and replaced with a quently with sera from STNP (25% of combinations testing
volume of undiluted serum equal to the volume of packed resin.
positive), recent seroconverters (17% of combinations testing
Suspensions were incubated at room temperature for 1 h with
positive), and progressors (17% of combinations testing posi-constant gentle mixing. Protein G–sepharose was then separated
tive). The breadth of neutralization was significantly greaterfrom the serum by low-speed centrifugation, and the serum was
for sera from LTNP compared with sera from all other groupscollected by pipette. Serum samples were subjected to two addi-
(P  .0014 compared with recent seroconverters, P  .0028tional absorption steps to ensure the removal of all IgG. Complete
removal of HIV-1–specific IgG was confirmed by Western immu- compared with progressors, and P  .0163 compared with
noblot analysis. STNP; 95% confidence level). The breadth of neutralization
Measurements of plasma viremia. HIV-1 RNA in plasma sam- with sera from STNP was no greater than with sera from recent
ples was quantified by the branched DNA method as described seroconverters or progressors (P  .05). There was also no
previously [27]. significant difference in neutralization sensitivity between NSI
Chemokine assays. Quantification of the chemokines
and SI viruses when sera from all infected persons were
RANTES and MIP-1b in serum samples was done with commer-
grouped as one for the analysis (P  .124).cially available ELISA kits as described by the supplier (R&D
Undiluted sera from LTNP neutralized the autologous virusSystems, Minneapolis). Levels of RANTES and MIP-1b were
obtained at the time of serum collection in all 3 cases examinedquantified when sufficient sample volumes were available. Levels
(table 3). These same sera had failed to neutralize the autolo-of MIP-1a were not measured because of a limited volume of
serum samples. gous virus at a 1:16 dilution previously [17]. Isolates from
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Table 2. Neutralization of primary isolates by undiluted sera obtained at different stages of HIV-1
infection.
Group, serum no. Neutralization of primary isolate
(weeks from
symptom onset) P59423 W25798 W79290 V89872 V67970 W179273
Recent seroconverters
15 (53) 96 { 0 97 { 1 96 { 2 19 { 30 66 { 5 71 { 10
23 (45) 14 { 34 28 { 19 98 { 1 4 { 25 4 { 17 03 { 39
27 (27) 39 { 16 65 { 5 91 { 2 44 { 19 27 { 19 52 { 12
30 (13) 17 { 63 37 { 31 30 { 14 9 { 18 09 { 39 06 { 32
45 (25) 56 { 21 69 { 3 91 { 9 51 { 19 30 { 24 51 { 22
46 (13) 22 { 23 61 { 7 80 { 7 23 { 20 011 { 34 35 { 18
Progressors
P59423 67 { 18 97 { 1 058 { 41 9 { 4 96 { 1 029 { 12
W25798 90 { 15 88 { 11 015 { 19 017 { 38 28 { 33 06 { 21
V89872 12 { 22 85 { 12 56 { 16 051 { 46 61 { 21 34 { 19
V67970 0 { 44 61 { 78 70 { 39 5 { 30 33 { 10 01 { 43
W179273 22 { 27 43 { 36 085 { 72 081 { 59 8 { 9 016 { 32
STNP
T00953 92 { 11 99 { 1 87 { 10 36 { 11 99 { 0 98 { 1
V91008 19 { 39 17 { 29 38 { 18 91 { 6 99 { 0 86 { 15
W97464 019 { 29 8 { 33 26 { 15 3 { 8 67 { 3 055 { 61
P46471 44 { 16 06 { 52 23 { 9 26 { 44 54 { 29 79 { 26
T84136 48 { 28 20 { 55 35 { 16 93 { 4 2 { 54 1 { 5
W55819 43 { 3 20 { 13 7 { 19 42 { 28 17 { 46 26 { 44
LTNP
1 100 100 100 85 { 10 90 { 8 100
2 82 { 18 87 { 11 03 { 77 38 { 24 98 { 3 95 { 6
3 96 { 5 96 { 4 47 { 33 42 { 21 100 97 { 2
9 39 { 11 51 { 58 028 { 127 31 { 21 62 { 19 74 { 21
10 100 100 015 { 126 53 { 4 100 83 { 24
17 70 { 12 60 { 17 81 { 23 11 { 19 88 { 9 23 { 14
HIV-1–negative subjects
D01 021 { 42 9 { 35 23 { 20 047 { 70 24 { 4 24 { 20
D02 044 { 30 32 { 14 35 { 1 080 { 28 2 { 22 038 { 31
D03 048 { 41 18 { 14 15 { 25 064 { 35 011 { 22 0 { 9
D04 040 { 7 23 { 9 9 { 8 062 { 13 29 { 19 042 { 37
D05 7 { 9 14 { 8 35 { 10 032 { 19 23 { 22 03 { 11
NOTE. Virus neutralization was measured in phytohemagglutinin-stimulated peripheral blood mononuclear cells
by using undiluted serum. Values are % reduction in p24 production relative to virus control (no test serum) in HIV-
1–negative subjects and relative to p24 production in presence of serum D01 for all others. Results are given as
average of triplicate wells { SD. Boldface type indicates 80% reduction (positive for neutralization). STNP, short-
term nonprogressors; LTNP, long-term nonprogressors.
progressors were neutralized by undiluted autologous serum in sepharose no longer had neutralizing activity. Loss of neutraliz-
ing activity could not be attributed to sample dilution duringonly 1 of 5 cases examined (table 2), whereas isolates from
STNP were neutralized by undiluted autologous serum in 0 of absorption, since the volume of processed samples never ex-
ceeded the original preabsorption volumes. These results4 cases examined (table 3).
Virus neutralization by undiluted serum is antibody-medi- strongly indicate that virus neutralization was mediated by IgG.
Antibody-independent neutralization was further assessed byated. We examined whether high concentrations of antiviral
cytokines or chemokines in undiluted serum were at least par- quantifying the concentration of the anti–HIV-1 chemokines,
RANTES and MIP-1b in serum samples (table 5). Many in-tially responsible for neutralizing activity. Protein G–sepharose
was used to remove the total IgG from 5 serum samples that fected persons had moderately elevated levels of RANTES
in their serum compared with levels in serum from healthy,had previously neutralized 1 or more primary isolates. Samples
were negative for anti–HIV-1 antibodies by Western blot anal- noninfected persons (14.8 ng/mL). Elevated levels were
mostly seen in sera from progressors, and these particular se-ysis after absorption (data not shown). Serum samples were
reevaluated for virus neutralization before and after absorption. rum samples had poor neutralizing activity against primary
isolates. Only 1 infected subject had a level of MIP-1b thatAs can be seen in table 4, samples absorbed with protein G–
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Table 3. Neutralization of primary isolates from long-term and Table 5. Analysis of serum chemokine concentrations at different
stages of HIV-1 infection.short-term nonprogressors (LTNP and STNP) by autologous serum.
Subject Status Neutralization of autologous virus Group, serum RANTES (ng/mL) MIP-1b (pg/mL)
Progressors18 LTNP 99 { 0
22 LTNP 94 { 3 W25798 77.8 NT
V89872 55.5 153.824 LTNP 99 { 0
P46471 STNP 30 { 18 V67970 68.0 20.3
STNPT00953 STNP 45 { 18
V91008 STNP 52 { 13 T00953 19.8 8.5
P46471 47.6 52.5W97464 STNP 32 { 9
T84136 10.6 25.0
NOTE. Undiluted serum from each subject was evaluated for neutralizing LTNP
antibodies against autologous isolate obtained at time of serum collection. 3 20.5 NT
Values are % reduction in p24 production in phytohemagglutinin-stimulated 10 18.3 NT
peripheral blood monocuclear cells and are given as average of triplicate wells 17 21.7 41.4{ SD.
18 17.6 58.6
Controls
D01 9.3 22.2
D02 13.5 54.2
was highly elevated relative to all others. This subject (V89872) D03 6.8 13.7
was a progressor whose serum rarely neutralized primary iso- D04 14.8 10.2
lates. Sera with the most potent neutralizing activity (i.e., serum
NOTE. LTNP, long-term nonprogressors; STNP, short-term nonpro-samples 3, 10, and T00953) had lower concentrations of these
gressors; NT, not tested.
chemokines than did the remaining sera that had poor or no
neutralizing activity. We conclude that virus neutralization us-
ing undiluted serum was unrelated to the concentration of anti– levels of plasma viremia of 105 RNA copies/mL at the earliest
time point examined. These levels subsequently declined and re-HIV-1 chemokines.
CD4 T cells, plasma virus loads, and serum antibody responses mained persistently low in 3 of them (patients 15, 23, and 30),
all of whom began antiretroviral therapy shortly after the firstduring primary infection. CD4 T cells, plasma virus, and serum
antibodies were quantified for HIV-1–infected persons starting at time point. The fourth patient with high levels of plasma virus
on entry continued to have high virus loads for 20 weeks of3–10 weeks from onset of symptoms and continuing for an addi-
tional 20–57 weeks thereafter (table 6). Four of 6 patients had follow-up (patient 45); this patient received no antiretroviral ther-
Table 4. Neutralization of primary isolates after removing IgG from serum samples.
Neutralization of primary isolate
Serum, IgG P59423 W25798 W79290 V89872 V67970 W179273 18
15 (53 weeks)
/ 82 { 4 95 { 2 94 { 4 NT NT NT NT
0 26 { 16 11 { 16 59 { 48 NT NT NT NT
T00953
/ NT NT NT NT 99 { 1 97 { 3 NT
0 NT NT NT NT 0 { 22 15 { 52 NT
V91008
/ NT NT NT 89 { 4 100 NT NT
0 NT NT NT 0 { 39 0 { 15 NT NT
10
/ NT 100 NT NT 100 NT NT
0 NT 0 { 37 NT NT 0 { 19 NT NT
18
/ NT NT NT NT NT NT 87 { 7
0 NT NT NT NT NT NT 14 { 45
NOTE. Undiluted sera were evaluated for neutralizing antibiotics against indicated primary isolate. Values are
% reduction in p24 production in phytohemagglutinin-stimulated peripheral blood mononuclear cells and are given
as average of triplicate wells { SD. NT, not tested. Samples were evaluated before (/) and after (0) IgG was
removed by absorption with protein G–sepharose.
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Table 6. CD4 T cells, plasma virus concentration, and antibody titers in primary HIV-1 infection.
Neutralizing antibody titer§
Patient,
weeks from CD4 Plasma ELISA Autologous
symptom onset* T cells/mm3 virus† titer‡ isolate IIIB MN SF-2
Patient 15
4 704 744,000 150 2 10 10 10
20 638 13,000 4050 4 10 24 393
25 542 19,000 4050 8 26 55 490
29 502 11,000 12,150 32 82 125 830
35 655 12,000 36,450 32 67 156 713
53 644 10,000 36,450 64 72 149 1932
Patient 23
10 756 171,000 450 2 10 23 14
18 523 137,000 1350 2 10 78 136
25 484 19,000 4050 2 10 157 520
29 385 31,000 4050 2 12 200 665
42 363 41,000 4050 2 10 342 661
45 391 58,000 12,150 2 10 199 1039
Patient 27
4 441 40,000 150 2 10 10 10
5 NT NT 450 2 10 10 10
6 313 10,000 450 2 22 29 10
11 395 10,000 1350 2 10 72 20
17 359 10,000 1350 2 14 24 840
27 357 15,000 4050 2 24 72 552
Patient 30
3 558 1,224,000 1350 2 10 10 10
7 679 37,000 1350 2 24 16 10
13 665 10,000 1350 2 32 23 226
18 655 12,000 1350 2 29 71 778
40 525 10,000 4050 2 48 144 2014
Patient 45
5 502 594,000 450 2 10 10 10
12 613 377,000 1350 2 10 10 10
20 651 297,000 1350 4 23 200 14
25 722 230,000 4050 16 43 137 20
Patient 46
5 848 43,000 4050 2 49 235 46
13 498 70,000 4050 2 120 236 143
30 436 10,000 1350 8 308 685 2335
51 400 500 450 32 227 544 762
62 488 500 1350 32 279 1317 2066
NOTE. NT, not tested.
* Virus was isolated from each patient at first time point indicated.
† Quantified by branched DNA assay. Values are copies of viral RNA/mL of plasma.
‡ Envelope-specific IgG was quantified by ELISA using HIV-1MN gp160 as antigen for detection.
§ Neutralizing antibodies were measured in human peripheral blood mononuclear cells against early autologous
isolate obtained1 month from onset of symptoms. Neutralizing antibodies to HIV-1IIIB and HIV-1MN were measured
in MT-2 cell–killing assay, whereas neutralizing antibodies to HIV-1SF-2 were measured in CEMx174 cell–killing
assay. Values are reciprocal of highest serum dilution to reduce production of p24 by 80% relative to negative
control serum D01 (primary isolates) or to result in 50% reduction in virus-induced cell killing (strains IIIB, MN,
and SF-2).
apy. Two remaining patients (27 and 46) had moderate levels of Envelope-specific IgG to HIV-1MN gp160 was detected by
ELISA at the earliest time point for all 6 patients (table 6).plasma virus at the earliest time point examined; these levels were
undetectable by weeks 5 and 30 of follow-up, respectively, and Seroconversion to the viral envelope glycoproteins at these
early time points was confirmed by HIV-1IIIB Western blotremained low or undetectable thereafter. The last 2 patients began
antiretroviral therapy shortly before plasma viremia declined to analysis (data not shown). Despite early seroconversion, devel-
opment of neutralizing antibodies to the early autologous iso-undetectable levels.
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late was delayed in most patients. For example, autologous ous autologous isolate than were sera from STNP or prog-
ressors.neutralizing antibodies in sera from patients 23, 27, and 30
were undetectable for 45, 27, and 18 weeks from onset of Broadly cross-reactive neutralizing antibodies in sera from
LTNP might be explained by responses against highly con-symptoms, respectively. Neutralizing antibodies in sera from
patient 15 were undetectable at 4 weeks but were present at a served epitopes, such as those recognized by the human mono-
clonal antibodies 2G12, IgG1b12, and 2F5 (reviewed in [28])titer of 1:4 by 20 weeks and rose to a titer 1:64 by 53 weeks.
Patient 45 developed low-titer (1:2) autologous neutralizing or by multiple responses to isolate-specific epitopes that accu-
mulated over time [29]. The sporadic neutralization of ourantibodies by week 5, and the titer increased to 1:16 by week
25. This patient received no antiretroviral therapy and main- primary isolates by many sera suggests that variable, isolate-
specific epitopes dominate the neutralizing antibody response.tained high levels of plasma HIV-1 RNA of 594,000–230,000
copies/mL during this period of time. Patient 46 developed It is reasonable to assume that the virus regularly mutates to
escape contemporaneous neutralizing antibodies against thesedetectable neutralizing antibodies to his early autologous iso-
late by week 13 (titer of 1:2), and the titer steadily rose to 1:32 variable epitopes. Consistent with this, Delwart et al. [30] ob-
served a high and constantly changing complexity of viral qua-by week 51 and was maintained at week 62. This latter patient
began antiretroviral therapy at about week 25, which was fol- sispecies in LTNP over time. This could create a wide range
of neutralization epitopes for antigen presentation and eventu-lowed by a drop in plasma HIV-1 RNA to undetectable levels
while titers of autologous neutralizing antibodies continued to ally lead to broadly cross-reactive neutralizing antibodies after
long-term nonprogressive infection.increase. Neutralizing antibodies to the early autologous isolate
were undetectable in sera from patients 23 and 27 throughout Early neutralizing antibody responses would have to be long-
lived to become cumulative over time as an explanation for thethe entire period of follow-up (i.e., 45 and 27 weeks from onset
of symptoms, respectively). broad responses in LTNP. Our results showed that neutralizing
antibodies against early isolates continue to rise in titer for atNeutralizing antibodies were detected within 5–20 weeks
from onset of symptoms when TCLA strains of HIV-1 were least 1 year (patients 15 and 46, table 6). Others have shown
that isolate-specific neutralizing antibody responses may beused for detection (table 6). These neutralizing antibodies were
most effective against strain SF-2, followed by MN and, to a maintained for at least 2–3 years [29, 31–33]. Whether these
responses can last for even longer periods of time has not beenmuch lesser degree, IIIB. Titers of neutralizing antibodies were
relatively low before 17 weeks for SF-2 and for a considerably addressed. Isolate-specific neutralizing antibody responses
would be maintained if the autologous virus persisted either aslonger period of time for MN and IIIB. For example, average
titers of neutralizing antibodies in sera from asymptomatic a minor population of replicating virus or as immune complexes
on follicular dendritic cells. Additional studies are needed toHIV-1–infected persons infected for 2–7 years are 1:345 and
1:680 for IIIB and MN, respectively [17], and 1:2259 for SF- determine more precisely the longevity of isolate-specific neu-
tralizing antibody responses in HIV-1–infected persons and2 (data not shown) in the same assay as that used above. On
the basis of these average titers and the data presented in table whether neutralization-escape variants arise periodically in
LTNP.6, the development of high-titer neutralizing antibodies to IIIB
and MN usually requires 25–53 weeks of infection. It should be noted that the titers of neutralizing antibodies
against primary isolates were low. Specifically, neutralizingFinally, 3 of 6 seroconverters showed signs of immune sup-
pression within 1 year from the onset of symptoms, as evi- antibodies detected in undiluted sera from progressors and
LTNP were much broader than those detected previously [17]denced by a drop in CD4 T cells below 500/mm3 (patients 23,
27, and 46). This immune suppression showed no obvious when the same serum samples were evaluated at a 1:16 dilution
against this panel of primary isolates. The earlier study alsocorrelation with plasma virus loads or neutralizing antibody
responses. determined that autologous neutralizing antibodies against vi-
ruses from 3 of 3 LTNP tested were undetectable at a 1:16
serum dilution, whereas here they were detected for all 3 LTNP
Discussion
when undiluted serum was used. Although the titers of these
neutralizing antibodies were low, they may still be significantOur results show that long-term nonprogressive HIV-1 infec-
tion is associated with broad neutralizing antibody responses in the host, where they are undiluted.
Our detection of virus neutralization with undiluted serumagainst primary isolates. Similar results have been reported
[17, 18], but those studies did not determine whether broad raised the possibility that antiviral cytokines, such as the inter-
ferons [25], or antiviral chemokines, such as RANTES, MIP-responses were unique to LTNP. Our results showed that neu-
tralizing antibodies in sera from LTNP are reactive against a 1a, MIP-1b [34], and SDF-1 [35, 36], were partially responsi-
ble. Clearly this was not the case for sera from HIV-1–negativebroader spectrum of primary isolates than are sera from prog-
ressors and non–immune-suppressed asymptomatic persons persons, since no neutralization was detected. It remained pos-
sible that the levels of antiviral cytokines and chemokines inwho had been infected for 7 years (STNP). In addition, sera
from LTNP were more likely to neutralize the contemporane- serum are elevated during HIV-1 infection. We examined this
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possibility and found that RANTES and MIP-1b were not infection could allow the virus to establish persistent infection.
In this regard, any means of accelerating the neutralizing anti-elevated in serum samples with broad neutralization activity.
Others have shown that serum chemokine levels are similar body response, such as by vaccination, might provide a clinical
benefit that is not realized by the natural response to infection.for LTNP and progressors and that these levels are below those
reported to block HIV-1 infection in vitro [37]. Additional Neutralization epitopes recognized by sera from LTNP would
be interesting to pursue for HIV-1 vaccine development. Weevidence that neutralization was antibody-mediated came from
lack of neutralization when IgG was removed from serum sam- also wish to emphasize that envelope-specific IgG was detected
very early during primary infection. Similar results have beenples. The virus neutralization detected with undiluted serum
samples was therefore most likely antibody-mediated. reported previously [2], and although these antibodies are non-
neutralizing, they might still provide a benefit by participatingOur improved detection of primary isolate neutralization
with undiluted serum led us to investigate how soon after pri- in antibody-dependent cellular cytotoxicity [7, 42] or in com-
plement-mediated clearance [43, 44]. Finally, it may be possi-mary infection autologous neutralizing antibodies could be de-
tected. Most studies agree that neutralizing antibodies are slow ble that continuous and high production of circulating virus
[45] will sometimes remove a significant portion of neutralizingto develop and do not correlate with the initial down-regulation
of plasma viremia during primary infection [5–7, 10]. The antibodies and that these antibodies are not replenished at a
pace to keep up with their removal. Our studies do not eliminateinitial down-regulation in plasma viremia in the patients fol-
lowed here was probably due to a combination of their immune this as a possible explanation for cases in which neutralizing
antibody titers were low or undetectable.response and antiretroviral therapy. Our results agree that autol-
ogous neutralizing antibodies against the early isolate are slow
to develop in many persons, even when measured with a 1:2
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